{"id":11709,"date":"2026-05-27T17:00:00","date_gmt":"2026-05-27T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=3ae88c741141305cbbcc8e0ae5ab9c5c"},"modified":"2026-05-27T17:00:00","modified_gmt":"2026-05-27T15:00:00","slug":"silence-therapeutics-to-participate-in-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=11709","title":{"rendered":"Silence Therapeutics to Participate in Jefferies Global Healthcare Conference"},"content":{"rendered":"

LONDON--(BUSINESS WIRE)--$SLN<\/a> #SenseofSilence<\/a>--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.<\/p><\/a><\/a>

\nA live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com<\/a>. An archived replay of the webcast will be available following the conference.<\/p>

\nAbout Silence Therapeutics\n<\/b>Silence Therapeutics is a global clinical-stage biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines created with proprietary siRNA (short interfering RNA) technology. Silence leverages its mRNAi GOLD\u2122 platform to create innovative siRNA therapies designed to precisely target and silence genes that cause disease. The Company is advancing a growing pipeline of siRNA product candidates targeting areas of high unmet need across rare and common diseases where treatments are limited or inadequate. For more information, please visit https:\/\/www.silence-therapeutics.com\/<\/a>.<\/p> Contacts<\/b>

\nInquiries:<\/b><\/p>

\nSilence Therapeutics plc<\/b>Gem Hopkins, VP, Head of IR and Corporate Communications\nir@silence-therapeutics.com<\/a>Tel: +1 (646) 637-3208<\/p>","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analys…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-11709","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11709"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11709\/revisions"}],"predecessor-version":[{"id":11710,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/11709\/revisions\/11710"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11709"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11709"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}